TRANSMITTAL OF ANNUAL REPORTS FOR DRUGS AND BIOLOGICS FOR HUMAN USE (21 CFR 314.81)			DATE SUBMI	TTED	Form Approved: OMB No. 0910-0001 Expiration Date: September 30, 2014 See OMB Statement on Reverse Side.				
NOTE: This report is required by law (21 USC 355; 21 CFR 314.81). Failure to report of result in withdrawal of approval of the New Drug or Biologics License Application				· oun	1. Application Type				
INSTRUCTIONS					2. Application Number				
Complete a transmittal for each application for which an annual report is being submitted. If submitting electronically, submit one copy of the form and annual						<i></i>			
report to FDA. If submitting in paper, submit two copies of the transmittal formalong with two copies of the annual report to FDA.					Report No. FDA Use O				
If any part of the annual report applies to more than one application, list in iten all other applications to which such parts apply.					APPLICANT NOTE Reference NDA and Y, or BLA numbers (entered on Acknowledgement Copy) in any subsequent correspondence regarding report.				
3. APPLICANT/AUTHORIZED U.S. AGENT 4. PH			NUMBER	I	5. TYPE OF REPORT (Check one)				
6. DRUG/BIOLOGIC NAME					<u> </u>	ANNUAL	· <u>L</u>	OTHER	
7. OTHER NDA OR BLA NUMBERS (List all	numbers if any part o	f report appli	es to more than o	ne numb	<i>er.</i>) 8. PEF	RIOD CO	VERED	BY REP	ORT
					FROM TO				
					YEAR	R MO	NTH	YEAR	MONTH
9. (Enter type of inform	REPORT INFORMAT mation attached unde 'INFORMATION IN	er "Identifica	tion." If you hav	e nothin	g to report,	enter No	ne.)		
TYPE OF INFORMATION IDENTIFICATION (Electro Volume No.(s) / Ta							tion or		
a. SUMMARY OF SIGNIFICANT NEW INFORMATION									
b. DISTRIBUTION DATA									
c. LABELING (Whether or not previously submitted)									
d. CHEMISTRY MANUFACTURING AND CONTROLS CHANGES SUPP	AC								
e. NONCLINICAL LABORATORY STUDIES	6								
f. CLINICAL DATA									
g. STATUS REPORTS OF POSTMARKET STUDY COMMITMENTS	ING								
h. STATUS OF OTHER POSTMARKETING STUDIES (e.g.,voluntary studies,CMC commitment studies, and product stabilit									
i. LOG OF OUTSTANDING REGULATOR' BUSINESS (Optional)	Y								
10. BLA REPORT INFORMATION REQUIRED (See § 601.70									
TYPE OF INFORMATION				CO	CONTENTS (Check box)				
a. ANNUAL PROGRESS REPORTS OF POSTMARKETING STUDIES									
11. TYPED NAME AND TITLE OF RESPON	SIBLE OFFICIAL OR	AGENT	13. SIGNATU	JRE					
12. APPLICANT'S RETURN ADDRESS						EDA IIS	E ONI	V	
Name of Sponsor / Applicant / Submitter				NDA	FDA USE ONLY NDA OR ANDA NUMBER				
Address 1			DATE	OF RECEI	PT				
Address 2				1					
City	State	ZIP or Po	stal Code	4					
Oity	Claic	ZIF UI FO	Jul Ooue						

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 5 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."